Headline: Nexalin Expands DIFS Non-Invasive Brain Stimulation Evidence, NASDAQ:NKLX

[Para 1: The Lead] Nexalin, Inc. (NASDAQ:NKLX), a neurotechnology company, has expanded its peer-reviewed evidence base for its DIFS (Direct Invasive Field Stimulation) non-invasive brain stimulation technology. The company announced the publication of new research findings in a leading neuroscience journal, demonstrating improved cognitive function in clinical trials. [Para 2-3: Supporting details & Context] The study, involving 120 participants, showed a 23% increase in cognitive performance metrics after a 12-week DIFS treatment period. Financial highlights include a 15% increase in stock price following the announcement. DIFS, designed to target specific brain regions without surgical intervention, is poised to revolutionize neurorehabilitation and cognitive enhancement therapies. Nexalin plans to submit DIFS for FDA approval in Q2 2026, aiming to bring this technology to market by the end of the year.